COVID-19 update included
The content of this report will be updated with the latest scenarios based on the global COVID-19 Pandemic

The Europe Human Growth Hormone Market would witness market growth of 7.9% CAGR during the forecast period (2019-2025).
In addition, initiatives taken by various government and private organizations to raise awareness of GH deficiencies and human growth hormone therapy are expected to drive the market. Every year, the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP), celebrates International Children’s Growth Awareness Day to raise awareness about early diagnosing and treating growth hormone disorders among humans, particularly children. Nevertheless, the high cost of HGH treatment and the multiple adverse effects associated with HGH could impede market growth over the forecast period. For example, as per UPMC Children’s Hospital in Pittsburgh, potential side effects of GH hormone therapy are hip, knee, or other joint pain; allergic reactions, including rash, swelling, or hives; and increased blood sugar levels.
The human growth hormone is very common among bodybuilders and athletes due to the many benefits it offers. Besides burning fat, it is also very effective for muscle building. Because of a possible muscle growth and strength benefit, bodybuilders and athletes who have been tempted to take performance-enhancing drugs and supplements such as steroids have taken HGH to achieve an athletic advantage, or for rapid, aesthetic muscle growth. Because digestion can break down HGH taken orally, it is injected when it is used as a supplementary drug. The bodybuilding industry was the first to find that HGH wasn’t just some drug to help growing children. This industry was also the first to quickly understand HGH’s anabolic properties and it could help them in achieving their only goal of a huge, youthful, well-ripped body.
Based on Application, the market is segmented into Small for Gestational Age, Prader-Willi Syndrome, Idiopathic Short Stature, Turner Syndrome, Growth Hormone Deficiency and Other Applications. Based on the type of Growth Hormone Deficiency, the application of Human Growth Hormone is studied across Pediatric Growth Hormone Deficiency and Adult Growth Hormone Deficiency. Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy, Specialty Pharmacy and Online Pharmacy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck Group, Teva Pharmaceuticals Industries Ltd., Ipsen Pharma Biotech SAS, Novartis AG (Sandoz International GmbH), Pfizer, Inc., F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Ferring Holdings SA, Novo Nordisk A/S, Eli Lilly and Company, and Anhui Anke Biotechnology Group Co., Ltd.
Scope of the Study
Market Segmentation:
By Application

  • Small for Gestational Age
  • Prader-Willi Syndrome
  • Idiopathic Short Stature
  • Turner Syndrome
  • Growth Hormone Deficiency and
  • ·Pediatric Growth Hormone Deficiency
  • ·Adult Growth Hormone Deficiency
  • Other Applications


By Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • Specialty Pharmacy
  • Online Pharmacy


By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe


Companies Profiled

  • Merck Group
  • Teva Pharmaceuticals Industries Ltd.
  • Ipsen Pharma Biotech SAS
  • Novartis AG (Sandoz International GmbH)
  • Pfizer, Inc.
  • F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
  • Ferring Holdings SA
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Anhui Anke Biotechnology Group Co., Ltd.


Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free